{"id":22953,"date":"2022-11-19T04:29:00","date_gmt":"2022-11-18T20:29:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=22953"},"modified":"2022-11-19T06:08:15","modified_gmt":"2022-11-18T22:08:15","slug":"jama%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e4%bc%8a%e7%bb%b4%e8%8f%8c%e7%b4%a0%e4%b8%8e%e5%ae%89%e6%85%b0%e5%89%82%e5%af%b9%e8%bd%bb%e4%b8%ad%e5%ba%a6%e6%96%b0%e5%86%a0%e8%82%ba%e7%82%8e","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=22953","title":{"rendered":"[JAMA\u53d1\u8868\u8bba\u6587]\uff1a\u4f0a\u7ef4\u83cc\u7d20\u4e0e\u5b89\u6170\u5242\u5bf9\u8f7b\u4e2d\u5ea6\u65b0\u51a0\u80ba\u708e\u95e8\u8bca\u60a3\u8005\u75c5\u60c5\u6301\u7eed\u6062\u590d\u65f6\u95f4\u7684\u5f71\u54cd"},"content":{"rendered":"\n

Original Investigation <\/p>\n\n\n\n

October 21, 2022<\/p>\n\n\n\n

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial<\/h1>\n\n\n\n

Susanna\u00a0Naggie,\u00a0David R.\u00a0Boulware,\u00a0Christopher J.\u00a0Lindsell,\u00a0et al<\/h3>\n\n\n\n

JAMA.\u00a0<\/em>Published online October 21, 2022. doi:10.1001\/jama.2022.18590<\/h3>\n\n\n\n

Key Points<\/p>\n\n\n\n

Question<\/strong>  Does ivermectin, 400 \u03bcg\/kg, daily for 3 days, compared with placebo, shorten symptom duration among adult (\u226530 years) outpatients in the US with symptomatic mild to moderate COVID-19?<\/p>\n\n\n\n

Findings<\/strong>  In this double-blinded, randomized, placebo-controlled platform trial conducted in the US during a period of Delta and Omicron variant predominance, and that included 1591 adult outpatients with COVID-19, the posterior probability of improvement in time to recovery in those treated with ivermectin vs placebo had a hazard ratio of 1.07, with a posterior probability of benefit of .91. This did not meet the prespecified threshold of posterior probability greater than .95.<\/p>\n\n\n\n

Meaning<\/strong>  These findings do not support the use of ivermectin in outpatients with mild to moderate COVID-19.<\/a><\/p>\n\n\n\n

Abstract<\/p>\n\n\n\n

Importance<\/strong>  The effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic COVID-19 is unknown.<\/p>\n\n\n\n

Objective<\/strong>  To evaluate the efficacy of ivermectin, 400 \u03bcg\/kg, daily for 3 days compared with placebo for the treatment of early mild to moderate COVID-19.<\/p>\n\n\n\n

Design, Setting, and Participants<\/strong>  ACTIV-6, an ongoing, decentralized, double-blind, randomized, placebo-controlled platform trial, was designed to evaluate repurposed therapies in outpatients with mild to moderate COVID-19. A total of 1591 participants aged 30 years and older with confirmed COVID-19, experiencing 2 or more symptoms of acute infection for 7 days or less, were enrolled from June 23, 2021, through February 4, 2022, with follow-up data through May 31, 2022, at 93 sites in the US.<\/p>\n\n\n\n

Interventions<\/strong>  Participants were randomized to receive ivermectin, 400 \u03bcg\/kg (n\u2009=\u2009817), daily for 3 days or placebo (n\u2009=\u2009774).<\/p>\n\n\n\n

Main Outcomes and Measures<\/strong>  Time to sustained recovery, defined as at least 3 consecutive days without symptoms. There were 7 secondary outcomes, including a composite of hospitalization or death by day 28.<\/p>\n\n\n\n

Results<\/strong>\u00a0\u00a0Among 1800 participants who were randomized (mean [SD] age, 48 [12] years; 932 women [58.6%]; 753 [47.3%] reported receiving at least 2 doses of a SARS-CoV-2 vaccine), 1591 completed the trial. The hazard ratio (HR) for improvement in time to recovery was 1.07 (95% credible interval [CrI], 0.96-1.17; posterior\u00a0P<\/em>\u00a0value [HR >1]\u2009=\u2009.91). The median time to recovery was 12 days (IQR, 11-13) in the ivermectin group and 13 days (IQR, 12-14) in the placebo group. There were 10 hospitalizations or deaths in the ivermectin group and 9 in the placebo group (1.2% vs 1.2%; HR, 1.1 [95% CrI, 0.4-2.6]). The most common serious adverse events were COVID-19 pneumonia (ivermectin [n\u2009=\u20095]; placebo [n\u2009=\u20097]) and venous thromboembolism (ivermectin [n\u2009=\u20091]; placebo [n\u2009=\u20095]).<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Conclusions and Relevance<\/strong>  Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19.<\/p>\n\n\n\n

Trial Registration<\/strong>  ClinicalTrials.gov Identifier: NCT04885530<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Original Investigation  October 21, 2022 […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/22953"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22953"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/22953\/revisions"}],"predecessor-version":[{"id":22954,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/22953\/revisions\/22954"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}